Pitolisant is a medication used to treat excessive daytime sleepiness in people with narcolepsy, with or without cataplexy. It acts as an inverse agonist of the histamine H₃ receptor, which increases the release of histamine in the brain and stimulates wakefulness.
Pitolisant (Dosage)
Pitolisant is a drug that acts as an inverse agonist and antagonist of the histamine H3 receptor in the central nervous system. It is mainly used for the treatment of narcolepsy with or without cataplexy and has also shown efficacy in the treatment of excessive sleepiness associated with other sleep disorders, such as obstructive sleep apnea.
MECHANISM OF ACTION
Pitolisant works by blocking H3 receptors in the brain, which increases histamine release. Histamine plays an important role in regulating wakefulness, so its increase helps to improve alertness in patients with excessive sleepiness. It has been evaluated as an alternative to traditional stimulants, with a lower risk of abuse.
Pitolisant may also modulate other neurotransmitter systems, increasing the release of acetylcholine, norepinephrine, and dopamine.
CONTRAINDICATIONS
Treatment with pitolisant is contraindicated in people with hypersensitivity to the drug or any of its excipients. Its use is also contraindicated in people with severe hepatic impairment and renal insufficiency, as both conditions can increase the concentration of the drug in the blood, considerably increasing the risk of adverse effects. Pitolisant may prolong the QT interval, so it is contraindicated in patients with long QT syndrome. Its use is not recommended in patients with epilepsy as it could lower the seizure threshold, nor in pregnant women.
SIDE EFFECTS
The most commonly reported side effects are insomnia, headaches, nausea, anxiety and irritability, increased heart rate, and prolongation of the QT interval (therefore, monitoring is required in patients with cardiovascular risk).
INTERACTIONS
Caution should be exercised when pitolisant is administered with CYP2D6 inhibitors (fluoxetine, paroxetine, or bupropion, among others) or CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, etc.). In these cases, the plasma concentration of pitolisant may be increased, so it may be necessary to adjust the dose of the drug.
When pitolisant is administered with CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, or St. John's wort) or CYP2D6 inducers (such as dexamethasone), it may be necessary to increase the dose of pitolisant to achieve the desired therapeutic effect.
In addition to the above, pitolisant may interact with drugs that prolong the QT interval (amiodarone, citalopram), stimulants (amphetamines, methylphenidate), benzodiazepines and CNS depressants, hormonal contraceptives, and alcohol.
BRAND NAMES
- Wakix®
- Ozawade®
Genes analyzed
Bibliography
Drugs@FDA. Drug Product pitolisant NDA 211150.
Pitolisant. European Medicines Agency.
Harwell V, Fasinu PS. Pitolisant and Other Histamine-3 Receptor Antagonists-An Update on Therapeutic Potentials and Clinical Prospects. Medicines (Basel). 2020 Sep 1;7(9):55.
